Molecular Diagnostics of Renal Cell Carcinoma in Cytopathology: Practical Applications for Fine-Needle Aspiration Biopsy

Renal cell carcinoma (RCC) comprises a heterogeneous group of renal epithelial neoplasms with distinct morphologic, immunophenotypic, and molecular characteristics that increasingly influence diagnosis, prognosis, hereditary risk assessment, and therapeutic decision-making. Advances in molecular pathology have reshaped RCC classification, culminating in the 2022 World Health Organization (WHO) framework, which includes a dedicated category of molecularly defined renal carcinomas. Concurrently, fine-needle aspiration biopsy (FNAB) has assumed an important role in the evaluation of RCC, particularly at metastatic sites, requiring cytopathologists to establish accurate diagnoses from limited material while preserving tissue for ancillary testing. Although much of the evidence base for RCC molecular pathology derives from surgical specimens, cytologic samples can support immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). This review provides a practical, entity-based overview of RCC molecular diagnostics from the perspective of the cytopathologist. For common RCCs and selected uncommon and molecularly defined renal tumors, we summarize characteristic cytomorphology, immunophenotype, molecular alterations, and the circumstances in which ancillary testing can refine classification or inform clinical management. Most conventional RCCs remain diagnosable through careful morphology and targeted IHC, whereas molecular testing is most informative in tumors with overlapping clear-cell, papillary, eosinophilic, or high-grade features and when a molecularly defined entity is suspected. Molecular findings may also raise concern for hereditary predisposition or identify clinically relevant alterations but should be interpreted within their morphologic and technical context. By combining cytomorphology with careful specimen stewardship, targeted IHC, and appropriately selected molecular testing, cytopathologists can use limited FNAB material to provide increasingly precise diagnoses that support appropriate clinical management.

Authors

Institutions

Publication Details

Journal
Journal of Molecular Pathology
Published
2026-11-20
DOI
https://doi.org/10.3390/jmp7040042
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular Diagnostics of Renal Cell Carcinoma in Cytopathology: Practical Applications for Fine-Needle Aspiration Biopsy

Jung Woo Kwon, Matthew L. Kleinjan, Melissa Yuwono Tjota, Tatjana Antic
3 links
Journal of Molecular Pathology
Renal cell carcinoma treatment
article

Molecular Diagnostics of Renal Cell Carcinoma in Cytopathology: Practical Applications for Fine-Needle Aspiration Biopsy

Jung Woo Kwon, Matthew L. Kleinjan, Melissa Yuwono Tjota, Tatjana Antic
article en

Abstract

Renal cell carcinoma (RCC) comprises a heterogeneous group of renal epithelial neoplasms with distinct morphologic, immunophenotypic, and molecular characteristics that increasingly influence diagnosis, prognosis, hereditary risk assessment, and therapeutic decision-making. Advances in molecular pathology have reshaped RCC classification, culminating in the 2022 World Health Organization (WHO) framework, which includes a dedicated category of molecularly defined renal carcinomas. Concurrently, fine-needle aspiration biopsy (FNAB) has assumed an important role in the evaluation of RCC, particularly at metastatic sites, requiring cytopathologists to establish accurate diagnoses from limited material while preserving tissue for ancillary testing. Although much of the evidence base for RCC molecular pathology derives from surgical specimens, cytologic samples can support immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). This review provides a practical, entity-based overview of RCC molecular diagnostics from the perspective of the cytopathologist. For common RCCs and selected uncommon and molecularly defined renal tumors, we summarize characteristic cytomorphology, immunophenotype, molecular alterations, and the circumstances in which ancillary testing can refine classification or inform clinical management. Most conventional RCCs remain diagnosable through careful morphology and targeted IHC, whereas molecular testing is most informative in tumors with overlapping clear-cell, papillary, eosinophilic, or high-grade features and when a molecularly defined entity is suspected. Molecular findings may also raise concern for hereditary predisposition or identify clinically relevant alterations but should be interpreted within their morphologic and technical context. By combining cytomorphology with careful specimen stewardship, targeted IHC, and appropriately selected molecular testing, cytopathologists can use limited FNAB material to provide increasingly precise diagnoses that support appropriate clinical management.

Journal of Molecular PathologyVol. 7(4)
University of Chicago Medical Center (US)
Good health and well-being
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon